Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:IMNM

Immunome Q3 2026 Earnings Date & Estimates

Immunome logo
$17.70 -0.57 (-3.09%)
As of 02:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immunome is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for November 9, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Immunome in Q3 2026

Immunome is expected to post earnings of -$0.6066 per share on revenue of $0.15 million. In the same quarter a year earlier Immunome reported -$0.65 per share. Immunome last reported on August 11, 2026, posting -$0.65 per share and missing the -$0.5138 consensus estimate. Immunome has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.6066
Expected Revenue
$0.15 million
Prior-Year EPS
-$0.65

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.65 (Missed by -$0.1362)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Immunome Q3 2026 Earnings FAQ

Immunome (NASDAQ:IMNM) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Immunome's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Immunome to post earnings of -$0.6066 per share for Q3 2026.

The consensus revenue estimate for Immunome is $0.15 million for Q3 2026.

Immunome Earnings Headlines

William Blair initiates coverage of Immunome at outperform
October 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/william-blair-initiates-coverage-of-immunome-at-outperform/ar-AA2epIfT
Immunome's Varegacestat: Could It Become The Second FDA-Approved Desmoid Tumor Treatment?
October 15, 2026  |  rttnews.comhttps://www.rttnews.com/3699466/immunome-s-varegacestat-could-it-become-the-second-fda-approved-desmoid-tumor-treatment.aspx
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 23 at 1:00 AM  |  Base Camp Trading (Ad)
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus
October 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immunome-imnm-following-fda-clearance-221601430.html
Immunome (IMNM) Gets a Hold from Stifel Nicolaus
October 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMNM/pressreleases/5002260/immunome-imnm-gets-a-hold-from-stifel-nicolaus/
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261006944020/en/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM) (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations. The company’s programs remain subject to clinical testing and regulatory review before any product can be commercialized.

View Immunome Profile
Earnings Tools